Novavax makes management promotions to support expanded clinical activity in 2014

In preparation for expanded clinical trial activities over the next two years

Novavax,a developer of vaccines for infectious diseases, has made number of promotions within its clinical operations group in preparation for expanded clinical trial activities in 2014 and 2015.

Gregory Glenn has been named as Senior Vice President, Research and Development. He joined Novavax in July 2010 as Senior Vice President, Chief Scientific Officer and in January 2011, was named Senior Vice President, Chief Medical Officer.

Glenn has spent 22 years in translational vaccine development, including discovery, preclinical and clinical development in viral, bacterial and parasitic vaccines.

Prior to joining Novavax, Glenn was Chief Scientific Officer and founder of Iomai Corporation, which was acquired by Intercell in 2008. He began his vaccine research career at the Walter Reed Army Institute of Research.

Louis Fries has become Vice President, Chief Medical Officer. He was Vice President of Clinical and Medical Affairs when he joined Novavax in April 2011. He had formerly served as Director of Clinical Development for GSK biologicals following the acquisition of ID Biomedical by GSK in 2005, and was previously Vice President of Clinical and Regulatory Affairs at ID Biomedical.

The third promotion is that of Nigel Thomas, who also joined Novavax in April 2011 as Executive Director, Clinical Operations.

Most recently, Thomas was Clinical Operations Director at Iomai from 2006 and through its acquisition by Intercell. He has previously held a variety of clinical operation positions in the biotechnology and CRO industry.

Companies